Makinen
TL2 Member · Frankfurt, DE
UK-based. Mostly the access and pricing categories.
Joined 8 July 2025 · last posted 9d · groups: regional-uk
86Posts here
2Topics
0Solutions
249Likes received
327Likes given
20Badges
128Days visited
1.4kPosts read
Most-liked posts
-
Revisiting: Holding a dose indefinitely: is there a documented downside? Started this topic · Practice › Dosing & titration · 11 Oct 2024 · 35 likes The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it.…
-
Reading order for a first week here, and what to skip until later Replied, post #53 · Start Here › Welcome · 26 Mar 2025 · 32 likes Off-topic posts that do not belong here belong in the Lounge instead. You are not in trouble if a moderator moves your post — they are just routing it to the right…
-
[2026 update] New subcategory: rationale and scope Replied, post #69 · Meta › Announcements · 16 Dec 2024 · 32 likes Scheduled maintenance: if the site is going offline for maintenance, advance notice will be posted here with the duration and scope.
-
About the Tirzepatide category Replied, post #5 · Compounds › Tirzepatide · 25 Jun 2025 · 28 likes The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a…
-
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #81 · Analytics › Mass spectrometry · 24 Mar 2026 · 26 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #53 · Access › Insurance & coverage · 4 Jul 2026 · 25 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
Where this member posts
| Category | Posts | Share |
|---|---|---|
| Practice | 18 | 21% |
| Evidence | 11 | 13% |
| Compounds | 9 | 10% |
| Analytics | 9 | 10% |
| Research Methods | 6 | 7% |
| Documentation | 4 | 5% |
Badges earned, in order
| Badge | Tier | Granted |
|---|---|---|
| First Reply | bronze | 10 Jul 2025 |
| Basic User | bronze | 12 Jul 2025 |
| Read the Guidelines | bronze | 14 Jul 2025 |
| First Link | bronze | 21 Jul 2025 |
| First Topic | bronze | 24 Jul 2025 |
| Welcome | bronze | 26 Jul 2025 |
| Member | bronze | 28 Jul 2025 |
| Generous | bronze | 31 Jul 2025 |
| First Quote | bronze | 11 Aug 2025 |
| Sourced | bronze | 12 Aug 2025 |
| Asked Well | bronze | 15 Aug 2025 |
| Reader | bronze | 20 Aug 2025 |
| First Tag | bronze | 11 Sep 2025 |
| Editor | bronze | 10 Oct 2025 |
| Logistics | bronze | 7 Dec 2025 |
| Nice Topic | bronze | 21 Dec 2025 |
| Nice Post | bronze | 22 Dec 2025 |
| Good Post | silver | 24 Dec 2025 |
| Good Topic | silver | 3 Feb 2026 |
| Anniversary | silver | 8 Jul 2026 |